Literature DB >> 24480711

Detailed phenotypic and genotypic characterization of bietti crystalline dystrophy.

Stephanie Halford1, Gerald Liew2, Donna S Mackay3, Panagiotis I Sergouniotis4, Richard Holt5, Suzanne Broadgate5, Emanuela V Volpi6, Louise Ocaka7, Anthony G Robson4, Graham E Holder4, Anthony T Moore4, Michel Michaelides4, Andrew R Webster4.   

Abstract

OBJECTIVE: To provide a detailed phenotype/genotype characterization of Bietti crystalline dystrophy (BCD).
DESIGN: Observational case series. PARTICIPANTS: Twenty patients from 17 families recruited from a multiethnic British population.
METHODS: Patients underwent color fundus photography, near-infrared (NIR) imaging, fundus autofluorescence (FAF) imaging, spectral domain optical coherence tomography (SD-OCT), and electroretinogram (ERG) assessment. The gene CYP4V2 was sequenced. MAIN OUTCOME MEASURES: Clinical, imaging, electrophysiologic, and molecular genetics findings.
RESULTS: Patients ranged in age from 19 to 72 years (median, 40 years), with a visual acuity of 6/5 to perception of light (median, 6/12). There was wide intrafamilial and interfamilial variability in clinical severity. The FAF imaging showed well-defined areas of retinal pigment epithelium (RPE) loss that corresponded on SD-OCT to well-demarcated areas of outer retinal atrophy. Retinal crystals were not evident on FAF imaging and were best visualized with NIR imaging. Spectral domain OCT showed them to be principally located on or in the RPE/Bruch's membrane complex. Disappearance of the crystals, revealed by serial recording, was associated with severe disruption and thinning of the RPE/Bruch's membrane complex. Cases with extensive RPE degeneration (N = 5) had ERGs consistent with generalized rod and cone dysfunction, but those with more focal RPE atrophy showed amplitude reduction without delay (N = 3), consistent with restricted loss of function, or that was normal (N = 2). Likely disease-causing variants were identified in 34 chromosomes from 17 families. Seven were novel, including p.Met66Arg, found in all 11 patients from 8 families of South Asian descent. This mutation appears to be associated with earlier onset (median age, 30 years) compared with other substitutions (median age, 41 years). Deletions of exon 7 were associated with more severe disease.
CONCLUSIONS: The phenotype is highly variable. Several novel variants are reported, including a highly prevalent substitution in patients of South Asian descent that is associated with earlier-onset disease. Autofluorescence showed sharply demarcated areas of RPE loss that coincided with abrupt edges of outer retinal atrophy on SD-OCT; crystals were generally situated on or in the RPE/Bruch's complex but could disappear over time with associated RPE disruption. These results support a role for the RPE in disease pathogenesis.
Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24480711     DOI: 10.1016/j.ophtha.2013.11.042

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  28 in total

1.  Adaptive optics imaging of the outer retinal tubules in Bietti's crystalline dystrophy.

Authors:  R Battu; M C Akkali; D Bhanushali; P Srinivasan; R Shetty; T T J M Berendschot; J S A G Schouten; C A Webers
Journal:  Eye (Lond)       Date:  2016-02-26       Impact factor: 3.775

2.  Detailed functional and structural phenotype of Bietti crystalline dystrophy associated with mutations in CYP4V2 complicated by choroidal neovascularization.

Authors:  Nicole M Fuerst; Leona Serrano; Grace Han; Jessica I W Morgan; Albert M Maguire; Bart P Leroy; Benjamin J Kim; Tomas S Aleman
Journal:  Ophthalmic Genet       Date:  2016-03-30       Impact factor: 1.803

3.  Longitudinal characterisation of function and structure of Bietti crystalline dystrophy: report on a novel homozygous mutation in CYP4V2.

Authors:  Catherine M Lockhart; Travis B Smith; Paul Yang; Malini Naidu; Allan E Rettie; Abhinav Nath; Richard Weleber; Edward J Kelly
Journal:  Br J Ophthalmol       Date:  2017-07-11       Impact factor: 4.638

4.  Generation and characterization of a murine model of Bietti crystalline dystrophy.

Authors:  Catherine M Lockhart; Mariko Nakano; Allan E Rettie; Edward J Kelly
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-12       Impact factor: 4.799

5.  Identification and population history of CYP4V2 mutations in patients with Bietti crystalline corneoretinal dystrophy.

Authors:  Xiaodong Jiao; Anren Li; Zi-Bing Jin; Xinjing Wang; Alessandro Iannaccone; Elias I Traboulsi; Michael B Gorin; Francesca Simonelli; J Fielding Hejtmancik
Journal:  Eur J Hum Genet       Date:  2017-01-04       Impact factor: 4.246

6.  A novel mutation of CYP4V2 gene associated with Bietti crystalline dystrophy complicated by choroidal neovascularization.

Authors:  Xin-Yao Han; Lin-Qi Zhang; Ji-Yang Tang; Lyu-Zhen Huang; Ran Tang; Jin-Feng Qu
Journal:  Int J Ophthalmol       Date:  2022-06-18       Impact factor: 1.645

7.  Crystalline retinopathy association with flupentixol intake.

Authors:  Pradeep Kumar; Raghav Ravani; Prateek Kakkar; Anu Sharma; Atul Kumar
Journal:  Int Ophthalmol       Date:  2017-07-04       Impact factor: 2.031

8.  Infrared imaging enhances retinal crystals in Bietti's crystalline dystrophy.

Authors:  Vikram S Brar; William H Benson
Journal:  Clin Ophthalmol       Date:  2015-04-15

9.  Molecular analysis and phenotypic study in 14 Chinese families with Bietti crystalline dystrophy.

Authors:  Houfa Yin; Chongfei Jin; Xiaoyun Fang; Qi Miao; Yingying Zhao; Zhiqing Chen; Zhaoan Su; Panpan Ye; Yao Wang; Jinfu Yin
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

10.  Expanding the Phenotypic and Genotypic Spectrum of Bietti Crystalline Dystrophy.

Authors:  Mariana Matioli da Palma; Fabiana Louise Motta; Mariana Vallim Salles; Caio Henrique Marques Texeira; André V Gomes; Ricardo Casaroli-Marano; Juliana Maria Ferraz Sallum
Journal:  Genes (Basel)       Date:  2021-05-10       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.